368 related articles for article (PubMed ID: 16932504)
1. Drug Insight: temozolomide as a treatment for malignant glioma--impact of a recent trial.
Mason WP; Cairncross JG
Nat Clin Pract Neurol; 2005 Dec; 1(2):88-95. PubMed ID: 16932504
[TBL] [Abstract][Full Text] [Related]
2. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.
Gorlia T; van den Bent MJ; Hegi ME; Mirimanoff RO; Weller M; Cairncross JG; Eisenhauer E; Belanger K; Brandes AA; Allgeier A; Lacombe D; Stupp R
Lancet Oncol; 2008 Jan; 9(1):29-38. PubMed ID: 18082451
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of disease: temozolomide and glioblastoma--look to the future.
Mrugala MM; Chamberlain MC
Nat Clin Pract Oncol; 2008 Aug; 5(8):476-86. PubMed ID: 18542116
[TBL] [Abstract][Full Text] [Related]
4. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
[TBL] [Abstract][Full Text] [Related]
5. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
6. New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy.
Dehdashti AR; Hegi ME; Regli L; Pica A; Stupp R
Neurosurg Focus; 2006 Apr; 20(4):E6. PubMed ID: 16709037
[TBL] [Abstract][Full Text] [Related]
7. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
[TBL] [Abstract][Full Text] [Related]
8. [Standards and new developments in the chemotherapy of glioblastomas].
Weller M
Dtsch Med Wochenschr; 2005 Oct; 130(40):2270-4. PubMed ID: 16208603
[TBL] [Abstract][Full Text] [Related]
9. [Glioma therapy up-date].
de la Fuente BP; Dalmau J; Rosenfeld M
Neurologia; 2007 Apr; 22(3):159-69. PubMed ID: 17364254
[TBL] [Abstract][Full Text] [Related]
10. Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?
Weller M; Wick W; Hegi ME; Stupp R; Tabatabai G
Future Oncol; 2010 Sep; 6(9):1407-14. PubMed ID: 20919826
[TBL] [Abstract][Full Text] [Related]
11. [Early postsurgical temozolomide treatment in newly diagnosed bad prognosis glioblastoma patients: Feasibility study].
Chaskis E; Luce S; Goldman S; Sadeghi N; Melot C; De Witte O; Devriendt D; Lefranc F
Bull Cancer; 2018; 105(7-8):664-670. PubMed ID: 29937336
[TBL] [Abstract][Full Text] [Related]
12. Optimal role of temozolomide in the treatment of malignant gliomas.
Stupp R; van den Bent MJ; Hegi ME
Curr Neurol Neurosci Rep; 2005 May; 5(3):198-206. PubMed ID: 15865885
[TBL] [Abstract][Full Text] [Related]
13. Going past the data for temozolomide.
Villano JL; Letarte N; Bressler LR
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1113-5. PubMed ID: 22147076
[TBL] [Abstract][Full Text] [Related]
14. Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
Jalali R; Basu A; Gupta T; Munshi A; Menon H; Sarin R; Goel A
Br J Neurosurg; 2007 Dec; 21(6):583-7. PubMed ID: 18071985
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y
Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172
[TBL] [Abstract][Full Text] [Related]
16. [Temozolomide in patients with a glioblastoma multiforme: new developments].
Bromberg JE; Postma TJ
Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1376-8. PubMed ID: 15997689
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.
Mirimanoff RO; Gorlia T; Mason W; Van den Bent MJ; Kortmann RD; Fisher B; Reni M; Brandes AA; Curschmann J; Villa S; Cairncross G; Allgeier A; Lacombe D; Stupp R
J Clin Oncol; 2006 Jun; 24(16):2563-9. PubMed ID: 16735709
[TBL] [Abstract][Full Text] [Related]
18. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
19. The evolution of chemoradiation for glioblastoma: a modern success story.
Mirimanoff RO
Curr Oncol Rep; 2006 Jan; 8(1):50-3. PubMed ID: 16464403
[TBL] [Abstract][Full Text] [Related]
20. Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.
Armstrong TS; Wefel JS; Wang M; Gilbert MR; Won M; Bottomley A; Mendoza TR; Coens C; Werner-Wasik M; Brachman DG; Choucair AK; Mehta M
J Clin Oncol; 2013 Nov; 31(32):4076-84. PubMed ID: 24101048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
